Teva has no plans to split up its business to separate its generic and branded interests, the company’s chief executive has confirmed, in response to questions over whether the firm’s increasing shift towards investing in its innovative assets meant that a company split could be on the cards.
Speaking at a meeting with local media in Tel Aviv, Israel, CEO Richard Francis referred to the firm’s “Pivot to Growth” strategy – launched midway through last year (see sidebar) –